Chemomab Therapeutics Reports 2024 Financials & Update
Ticker: CMMB · Form: 6-K · Filed: Mar 3, 2025 · CIK: 1534248
| Field | Detail |
|---|---|
| Company | Chemomab Therapeutics LTD. (CMMB) |
| Form Type | 6-K |
| Filed Date | Mar 3, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-results, corporate-update, biotech
TL;DR
Chemomab dropped its 2024 year-end financials on 3/3/25. Check it out.
AI Summary
Chemomab Therapeutics Ltd. announced its financial results for the year ended and fourth quarter of 2024 on March 3, 2025. The company, formerly known as Anchiano Therapeutics Ltd. and BioCancell Ltd., is a foreign private issuer filing a Form 6-K report. The filing details their financial performance and provides a corporate update.
Why It Matters
This filing provides investors with the latest financial performance and operational status of Chemomab Therapeutics, crucial for understanding the company's current health and future prospects.
Risk Assessment
Risk Level: medium — As a clinical-stage biotechnology company, Chemomab Therapeutics faces inherent risks related to drug development, regulatory approvals, and market adoption.
Key Players & Entities
- Chemomab Therapeutics Ltd. (company) — Registrant
- Anchiano Therapeutics Ltd. (company) — Former company name
- BioCancell Ltd. (company) — Former company name
- March 3, 2025 (date) — Date of press release and filing
- 2024 (date) — Reporting period for financial results
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose is to report the year-end and fourth quarter 2024 financial results and provide a corporate update for Chemomab Therapeutics Ltd., as announced in their press release on March 3, 2025.
When did Chemomab Therapeutics Ltd. announce its financial results?
Chemomab Therapeutics Ltd. announced its financial results for the year end and fourth quarter of 2024 on March 3, 2025.
What were Chemomab Therapeutics Ltd.'s previous names?
Chemomab Therapeutics Ltd. was formerly known as Anchiano Therapeutics Ltd. and BioCancell Ltd.
Under which form does Chemomab Therapeutics Ltd. file its annual reports?
Chemomab Therapeutics Ltd. files its annual reports under cover of Form 20-F.
Where is Chemomab Therapeutics Ltd. located?
Chemomab Therapeutics Ltd.'s principal executive offices are located at Kiryat Atidim, Building 7, Tel-Aviv, Israel.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on March 3, 2025 regarding Chemomab Therapeutics Ltd. (CMMB).